Renal Division, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Vasc Med. 2013 Apr;18(2):85-91. doi: 10.1177/1358863X13483864.
Pentraxin 3 (PTX3) is a novel inflammatory cytokine produced in atherosclerotic plaque. We hypothesized that this marker may be a better predictor of peripheral artery disease (PAD) than C-reactive protein (CRP) in hemodialysis (HD) patients. The ankle-brachial index (ABI) was measured in HD patients. PTX3 levels in 116 HD patients and 30 healthy blood donors were measured by ELISA. A total of 116 HD patients (age: 56.44 ± 14.08 years) were enrolled; 21 (18%) patients had PAD. PTX3 was significantly higher in PAD versus non-PAD patients (5.55 ± 2.63 vs 2.32 ± 1.29 ng/mL; p < 0.001). In a univariate analysis, ABI correlated significantly with age, blood glucose and triglycerides, and plasma PTX3 (r = -0.548, p < 0.001) and high-sensitivity (hs)CRP (r = -0.495, p < 0.001). Using ROC curve analysis for PAD, PTX3 (cut-off value 4.06 ng/mL, AUC 0.901, p < 0.0001) showed a significantly better positive predictive value than hsCRP (cut-off value 3.33 mg/L, AUC 0.640, p < 0.05). Logistic regression analysis further confirmed that PTX3 (OR = 9.755, p = 0.001) was an independent predictor of PAD. In conclusion, we demonstrated that PTX3 may be a better marker of PAD than hsCRP, and independently correlated with PAD in HD patients.
五聚素 3（PTX3）是动脉粥样硬化斑块中产生的一种新型炎症细胞因子。我们假设，与 C 反应蛋白（CRP）相比，这种标志物可能是血液透析（HD）患者外周动脉疾病（PAD）更好的预测指标。我们在 HD 患者中测量了踝肱指数（ABI）。通过 ELISA 测量了 116 名 HD 患者和 30 名健康献血者的 PTX3 水平。共纳入 116 名 HD 患者（年龄：56.44±14.08 岁）；21 名（18%）患者患有 PAD。PAD 患者的 PTX3 明显高于非 PAD 患者（5.55±2.63 与 2.32±1.29ng/mL；p<0.001）。在单变量分析中，ABI 与年龄、血糖和甘油三酯以及血浆 PTX3（r=-0.548，p<0.001）和高敏（hs）CRP（r=-0.495，p<0.001）显著相关。使用 ROC 曲线分析 PAD，PTX3（截断值 4.06ng/mL，AUC 0.901，p<0.0001）的阳性预测值明显优于 hsCRP（截断值 3.33mg/L，AUC 0.640，p<0.05）。Logistic 回归分析进一步证实，PTX3（OR=9.755，p=0.001）是 PAD 的独立预测因子。总之，我们证明，PTX3 可能是比 hsCRP 更好的 PAD 标志物，并且与 HD 患者的 PAD 独立相关。
